FDA Grants Priority Review to J&J's Rybrevant Faspro for Head and Neck Cancer
JNJ sits 59% above its 52-week low of $164.23.
Summary
The FDA accepted a supplemental Biologics License Application for Rybrevant Faspro as a subcutaneous treatment for advanced head and neck cancer, granting Priority Review. This positions the drug as a potential first-in-class EGFR- and MET-targeted therapy in an indication with limited options. The news follows a series of positive pipeline developments for J&J, including the recent Erleada trial success and strong Talvey/Darzalex data, reinforcing the oncology franchise's momentum. A Priority Review designation typically shortens the review clock to six months, meaning a decision could come by early 2027. With the company's recent EPS guidance cut due to acquisition costs, a new blockbuster indication would help offset Stelara's biosimilar erosion.
At the time of this announcement, JNJ was trading at $260.52 on NYSE in the Life Sciences sector, with a market capitalization of approximately $639.9B. The 52-week trading range was $164.23 to $274.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.